Pharmacotherapy for Depression in Long-Term Care: A Real-World EHR Study

This retrospective study of over 1.6 million U.S. long-term care residents reveals that while 81.7% of those diagnosed with depression received recommended pharmacotherapy, significant disparities persist, with Black residents and those in socioeconomically vulnerable facilities facing lower odds of treatment.

The Gist

Imagine a massive, bustling city called Long-Term Care (LTC). This city is home to over 1.6 million elderly residents who need extra help with daily life. In this city, a common "fog" often rolls in, making residents feel sad, hopeless, or unable to enjoy their days. We call this fog depression.

This research paper is like a giant map drawn by a team of detectives (the researchers) who looked at the digital records of this entire city to answer three big questions:

1. How many people with this "fog" are actually getting medicine to clear it up?
2. Who is getting the medicine, and who is being left out?
3. Why does this happen?

Here is the story of their findings, explained simply.

1. The Good News: Most People Are Getting Help

The detectives found that 82 out of every 100 residents who were diagnosed with depression were given a prescription to help. That's a pretty high number!

Think of the medicine like a key that unlocks the door to feeling better. The most popular keys were a type called SSRIs (about 60% of the keys used) and a mixed bag of other antidepressants (about 42%). It's like a pharmacy shelf where these specific bottles are the bestsellers.

2. The Bad News: Some Doors Are Locked

Even though most people got a key, the map revealed some very unfair patterns. It turns out, who gets a key depends heavily on who you are and where you live.

• The Race Gap: If a resident was Black or African American, they were significantly less likely to get a key compared to White residents. It's as if the pharmacy had a hidden rule that made it harder for certain people to walk through the door.
• The Wealth Gap: If the nursing home was located in a neighborhood that was struggling financially (high poverty, unemployment), the residents there were less likely to get treatment. It's like a town with fewer resources; the "mental health doctors" and support staff are harder to find, so fewer keys get handed out.
• The Health Paradox: Interestingly, if a resident had diabetes or high cholesterol (hyperlipidemia) but wasn't taking medicine for it, they were less likely to get depression medicine too. It seems that if the system misses one health problem, it often misses the others, too.

3. The Surprising Helpers

The map also showed who was more likely to get help.

• The "Double Trouble" Group: Residents who had vascular dementia (a type of memory loss caused by blood flow issues) or who were already taking medicine for high cholesterol were more likely to get depression medicine.
• Why? Think of it like a traffic cop. If a resident is already seeing a doctor regularly for their cholesterol or dementia, that doctor is more likely to notice the "fog" of depression and hand them a key. Being on the "radar" of the medical system helps you get treated for everything.

4. Why Does This Happen? (The Metaphor)

Imagine the nursing home system as a garden.

• The Plants: The residents are the plants.
• The Sunlight: The treatment (medicine) is the sunlight.
• The Problem: The study found that while most plants are getting sunlight, some specific plants (Black residents, those in poor neighborhoods) are stuck in the shade.

Why are they in the shade?

• Stigma: Sometimes, people are afraid to ask for help or don't trust the gardeners (doctors).
• Staffing: In poorer neighborhoods, the garden might not have enough gardeners to check on every plant.
• Focus: Sometimes, the gardeners are so busy fixing the "leaves" (physical problems like diabetes) that they forget to check the "roots" (mental health).

The Bottom Line

This study is a wake-up call. It says, "Hey, we are doing a good job treating depression in nursing homes, but we are leaving some people behind."

The researchers are asking the gardeners (doctors, nurses, and policymakers) to:

1. Check the whole garden: Make sure no one is hiding in the shade because of their race or where they live.
2. Train the gardeners: Teach them to spot the "fog" of depression even when they are busy fixing other problems.
3. Build more greenhouses: Bring more mental health experts into the poorer neighborhoods so everyone has equal access to the sunlight they need to grow.

In short: We have the medicine to help, but we need to make sure we hand it out fairly to everyone, no matter their background or their zip code.

Technical Summary

1. Problem Statement

Depression is highly prevalent among older adults in Long-Term Care (LTC) facilities, affecting an estimated 10% of residents with Major Depressive Disorder (MDD) and 29% with significant depressive symptoms. Despite its impact on functional decline and mortality, depression in LTC is frequently underrecognized and undertreated.

• Key Issues:
  • Documentation Gaps: Nearly one-third of residents without a recorded depression diagnosis are prescribed antidepressants (suggesting off-label use or poor documentation), while ~25% of those with a documented diagnosis receive no pharmacotherapy.
  • Structural Barriers: Many facilities lack psychiatric consultation, and treatment decisions are often hindered by concerns regarding adverse drug events, polypharmacy, and fall risks.
  • Disparities: Previous literature suggests treatment access varies by age, mobility, and race, but recent large-scale trends in the U.S. are not well-understood.

2. Methodology

Study Design: Retrospective, observational study using real-world electronic health record (EHR) data.

Data Source:

• Database: PointClickCare Life Sciences database.
• Scope: 1,675,873 U.S. LTC residents (including assisted living, senior living, and skilled nursing facilities) from January 1, 2025, to April 30, 2025.
• Sample: 358,425 residents with a documented depression diagnosis were identified for the final analysis.

Inclusion Criteria:

• Residents with at least one day of residence in an LTC/SNF facility during the study period.
• At least one active diagnosis of depression (ICD-10 codes: F33 series for MDD, F32.A for Unspecified, F33.8 for Other).

Variables & Exposures:

• Primary Outcome: Receipt of pharmacological treatment. Residents were classified as "treated" if they had a medication order for an antidepressant class aligned with American Psychological Association (APA) guidelines.
  • Classes included: SSRIs, SNRIs, Serotonin Modulators/Stimulators, Tricyclics, NDRIs, and MAOIs.
• Covariates:
  • Demographics: Age, sex, race/ethnicity, insurance type, facility region.
  • Clinical: Comorbidities (Diabetes, Hyperlipidemia, Vascular Dementia), Charlson Comorbidity Index (CCI), medication counts.
  • Facility: Geographic location and Social Vulnerability Index (SVI) of the facility's location.

Statistical Analysis:

• Descriptive: Means/SDs for continuous variables; counts/percentages for categorical variables.
• Inferential: Multivariable logistic regression was used to estimate the odds ratios (OR) of receiving treatment, adjusting for demographic, clinical, and facility-level characteristics.

3. Key Contributions

• Scale: This is one of the largest studies to date, analyzing over 1.6 million residents and nearly 360,000 diagnosed cases of depression in U.S. LTC.
• Real-World Evidence: Utilizes comprehensive EHR data rather than self-reported surveys or limited administrative claims, capturing actual medication orders and clinical diagnoses.
• Equity Focus: Specifically quantifies disparities in pharmacotherapy access based on race, socioeconomic status of the facility location, and comorbid conditions.
• Temporal Relevance: Provides data from 2025, offering a current snapshot of treatment patterns post-pandemic.

4. Key Results

Overall Treatment Rates:

• 81.7% of residents with a documented depression diagnosis received at least one pharmacologic treatment order.
• Most Common Classes:
  • Selective Serotonin Reuptake Inhibitors (SSRIs): 59.8%
  • Miscellaneous Antidepressants (e.g., vortioxetine, mirtazapine, trazodone): 42.3%
  • Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs): 22.3%

Predictors of Treatment (Multivariable Logistic Regression):

• Higher Odds of Treatment:
  • Diagnosis of Vascular Dementia.
  • Presence of Hyperlipidemia medication orders (suggesting better overall medication management/refill adherence).
  • Specific depression diagnoses (Unspecified Depression and MDD were most predictive).
• Lower Odds of Treatment (Disparities):
  • Race: Black or African American residents had the lowest odds (OR = 0.71).
  • Comorbidities: Residents with Diabetes or a Hyperlipidemia diagnosis (without medication orders) were less likely to be treated.
  • Socioeconomic Context: Residents in facilities located in areas with high Social Vulnerability Index (SVI) scores (indicating poverty, unemployment, lack of education) had significantly lower treatment odds.

Demographic Breakdown:

• The cohort was predominantly female (62.3%) and White (72.5%).
• Treatment rates varied slightly by region, with the West showing the lowest rate (77.3%) compared to the South (83.7%).

5. Significance and Implications

Clinical & Policy Implications:

• Persistent Inequities: Despite high overall treatment rates, significant disparities exist. The study highlights that race and the socioeconomic status of the facility's location are strong independent predictors of whether a resident receives evidence-based care.
• Comorbidity Management: The finding that residents with vascular dementia and those on hyperlipidemia meds are more likely to be treated suggests that integrated care models (managing multiple chronic conditions) may improve depression detection and treatment. Conversely, the lower treatment rates for those with diabetes diagnoses suggest a need for better screening in this subgroup.
• Resource Allocation: Facilities in socially vulnerable areas likely suffer from staffing disparities and limited access to psychiatric consultation, necessitating targeted policy interventions and resource allocation.

Limitations:

• Cross-Sectional Design: Precludes causal inference.
• Scope: Only analyzed pharmacotherapy; non-pharmacological interventions (e.g., psychotherapy) were not captured.
• Generalizability: Findings are specific to LTC populations using PointClickCare EHR and may not reflect community-dwelling seniors.

Conclusion:
While the majority of LTC residents with depression receive recommended pharmacotherapy, the study reveals a "treatment gap" driven by racial bias and socioeconomic factors. The authors call for improved screening practices, equitable prescribing protocols, and enhanced clinical resources in socially vulnerable settings to ensure all residents receive consistent, evidence-based depression care.